Trials / Completed
CompletedNCT00502242
Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating The Effect of Ramipril On Urinary Protein Excretion In Maintenance Renal Transplant Patients Converted To Sirolimus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 229 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to determine the efficacy of ramipril in preventing a urinary protein to creatinine ratio (U p/c) greater than 0.5 following conversion to sirolimus from a calcineurin inhibitor (CNI) in maintenance kidney transplant patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ramipril | Capsule - initial treatment is 5 mg (active)- oral - once per day |
| DRUG | ramipril | Capsule - initial treatment is 5 mg (placebo) - oral - once per day |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2007-07-17
- Last updated
- 2014-08-27
- Results posted
- 2014-08-27
Locations
49 sites across 12 countries: United States, Argentina, Australia, Austria, Brazil, Canada, Germany, Hungary, Israel, Mexico, Poland, South Africa
Source: ClinicalTrials.gov record NCT00502242. Inclusion in this directory is not an endorsement.